{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:12:21Z","timestamp":1793923941699,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["DRCRPG-Nov22\/100007"],"award-info":[{"award-number":["DRCRPG-Nov22\/100007"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A26813"],"award-info":[{"award-number":["A26813"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"publisher","award":["SBF0091103"],"award-info":[{"award-number":["SBF0091103"]}],"id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","award":["RGR2232323"],"award-info":[{"award-number":["RGR2232323"]}],"id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["FAF-C\/2018\/1297"],"award-info":[{"award-number":["FAF-C\/2018\/1297"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/Y003365\/1"],"award-info":[{"award-number":["MR\/Y003365\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019418","name":"NIHR Maudsley Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203309"],"award-info":[{"award-number":["NIHR203309"]}],"id":[{"id":"10.13039\/100019418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010089","name":"JGW Patterson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF 2023R1A2C2004339"],"award-info":[{"award-number":["NRF 2023R1A2C2004339"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jhep.2026.05.018","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:30:15Z","timestamp":1781566215000},"page":"899-911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma"],"prefix":"10.1016","volume":"85","author":[{"given":"Pasquale","family":"Lombardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Ramon-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6896-5866","authenticated-orcid":false,"given":"Rabial Q.","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2639-4135","authenticated-orcid":false,"given":"Leonardo","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Francesca","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6520-195X","authenticated-orcid":false,"given":"Zhongguo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7116-2451","authenticated-orcid":false,"given":"George","family":"Merces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-2504","authenticated-orcid":false,"given":"Sarah","family":"Cappuyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Angela","family":"Maria Fulgenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9164-3671","authenticated-orcid":false,"given":"Antonio","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7582-8235","authenticated-orcid":false,"given":"Aria","family":"Torkpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Celsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3800-5678","authenticated-orcid":false,"given":"Bernardo","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-3912","authenticated-orcid":false,"given":"Fionnuala","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5903-8191","authenticated-orcid":false,"given":"Thomas U.","family":"Marron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-532X","authenticated-orcid":false,"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-5425","authenticated-orcid":false,"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7492-2484","authenticated-orcid":false,"given":"Pei-Chang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoshi","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-8908","authenticated-orcid":false,"given":"Ryan","family":"Po-Ting Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0402-4176","authenticated-orcid":false,"given":"Andrea","family":"Dalbeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Vivaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-8989","authenticated-orcid":false,"given":"Gianluca","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Rohlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"von Felden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Kaseb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8294-0992","authenticated-orcid":false,"given":"Peter R.","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0738-417X","authenticated-orcid":false,"given":"Wei-Fan","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-3615","authenticated-orcid":false,"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4629-7762","authenticated-orcid":false,"given":"Alessandro","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-2430","authenticated-orcid":false,"given":"Robin Kate","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-6168","authenticated-orcid":false,"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9740-0155","authenticated-orcid":false,"given":"Mario","family":"Pirisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3540-0234","authenticated-orcid":false,"given":"Falah","family":"Jabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Rakaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0946-3859","authenticated-orcid":false,"given":"Giuseppe","family":"Cabibbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Camm\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-1845","authenticated-orcid":false,"given":"Fabio","family":"Piscaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2461-6806","authenticated-orcid":false,"given":"Sohyun","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Jun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Dekervel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0782-8647","authenticated-orcid":false,"given":"Tim","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen L.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Bengsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0950-243X","authenticated-orcid":false,"given":"Derek A.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-5812","authenticated-orcid":false,"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-2396","authenticated-orcid":false,"given":"Jack","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-0103","authenticated-orcid":false,"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jhep.2026.05.018_bib1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2026.05.018_bib2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2026.05.018_bib3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jhep.2026.05.018_bib4","article-title":"Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials","volume":"5","author":"Fulgenzi","year":"2023","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.jhep.2026.05.018_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.jhep.2026.05.018_bib6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.05.018_bib7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejca.2022.08.024","article-title":"Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: results of the AB-real study","volume":"175","author":"Fulgenzi","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jhep.2026.05.018_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/HEP.0000000000000636","article-title":"Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab","volume":"79","author":"Campani","year":"2024","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2026.05.018_bib9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jhep.2026.05.018_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.jhep.2026.05.018_bib11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","article-title":"Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment","volume":"81","author":"Celsa","year":"2025","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2026.05.018_bib12","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jhep.2024.12.016","article-title":"Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma","volume":"82","author":"Cappuyns","year":"2024","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jhep.2026.05.018_bib13","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jhep.2026.05.018_bib14","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","article-title":"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.jhep.2026.05.018_bib15","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jhep.2026.05.018_bib16","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1038\/s41467-023-43381-1","article-title":"PD-1(-) CD45RA(+) effector-memory CD8 T cells and CXCL10(+) macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma","volume":"14","author":"Cappuyns","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jhep.2026.05.018_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2022.4933","article-title":"Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC","volume":"9","author":"Rakaee","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2026.05.018_bib18","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.dld.2024.01.012","article-title":"Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma","volume":"56","author":"Manfredi","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2026.05.018_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103773","article-title":"Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: a systematic review","volume":"177","author":"Presti","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.jhep.2026.05.018_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jhep.2026.05.018_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-gamma in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark Res"},{"issue":"8","key":"10.1016\/j.jhep.2026.05.018_bib22","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41416-018-0220-9","article-title":"Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy","volume":"119","author":"Fumet","year":"2018","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.jhep.2026.05.018_bib23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1158\/1541-7786.MCR-18-0455","article-title":"Loss of Fas expression and function is coupled with colon cancer resistance to immune checkpoint inhibitor immunotherapy","volume":"17","author":"Xiao","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10.1016\/j.jhep.2026.05.018_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/SLA.0b013e3181a77e59","article-title":"Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma","volume":"250","author":"Halazun","year":"2009","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.jhep.2026.05.018_bib25","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","article-title":"Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer","volume":"89","author":"Forrest","year":"2003","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jhep.2026.05.018_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000270","article-title":"Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression","volume":"78","author":"Guillot","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2026.05.018_bib27","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","article-title":"Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer","volume":"13","author":"Qi","year":"2022","journal-title":"Nat Commun"},{"issue":"6657","key":"10.1016\/j.jhep.2026.05.018_bib28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1126\/science.ade2292","article-title":"CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers","volume":"381","author":"Bill","year":"2023","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jhep.2026.05.018_bib29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","article-title":"The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer","volume":"88","author":"Guthrie","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4_suppl","key":"10.1016\/j.jhep.2026.05.018_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS631","article-title":"A phase I\/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC)","volume":"41","author":"Evans","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jhep.2026.05.018_bib31","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1136\/gutjnl-2021-326259","article-title":"CXCR2 inhibition enables NASH-HCC immunotherapy","volume":"71","author":"Leslie","year":"2022","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.jhep.2026.05.018_bib32","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1042\/EBC20220245","article-title":"Harnessing neutrophil plasticity for HCC immunotherapy","volume":"67","author":"Ramon-Gil","year":"2023","journal-title":"Essays Biochem"},{"key":"10.1016\/j.jhep.2026.05.018_bib33","article-title":"Effective anti-tumor response by TIGIT blockade associated with FcgammaR engagement and myeloid cell activation","volume":"11","author":"Han","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jhep.2026.05.018_bib34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1158\/2326-6066.CIR-23-0568","article-title":"ILT2 and ILT4 drive myeloid suppression via both overlapping and distinct mechanisms","volume":"12","author":"Tian","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.jhep.2026.05.018_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013697","article-title":"Targeting macrophage-derived SPP1 enhances CD8 T cell infiltration via ROS-DNA fragment\/cGAS-STING\/STAT1-mediated CXCL9\/10 in tumor microenvironment","volume":"14","author":"Wang","year":"2026","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782602605X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782602605X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:59:27Z","timestamp":1792083567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882782602605X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S016882782602605X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.05.018","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}